Celgene Corporation (NASDAQ:CELG) recently came out with the details about its data from the Phase III trial, RELIEF tried for dermatology drug Otezla. The late-breaking oral presentation was made at the 2018 American Academy of Dermatology (“AAD”) Annual Meeting.
According to reports, the phase III RELIEF is a randomized, placebo-controlled, double-blind study that evaluates Otezla twice daily in 207 patients suffering from active Behcet’s Disease previously treated with at least one type of topical or systemic medication. The results from the study showed statistically significant reductions in the oral ulcers with Otezla versus placebo through week 12.
Celgene is planning to submit supplemental New Drug Applications for Otezla BID for the active Behcet’s Disease treatment with oral ulcers in the U.S. and Japan in the second part of 2018. The company is also planning to make submission of a type II Variation to the Marketing Authorization Application in EU in 2019.
Otezla has already received approval for treating patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy in the U.S and for treating adults suffering from active psoriatic arthritis. Reports indicate that Otezla sales have escalated in the last quarter of 2017 after a slowdown in the third quarter.
John Weiland Elected To Board Of Directors Of Celgene Corporation
The integrated global biopharmaceutical company recently announced that John Weiland has been elected to its Board of Directors. Mr. Weiland has been in the healthcare industry since more than 30 years and recently also served as the Chief Operating Officer and President of C.R. Bard, Inc. and handled the worldwide responsibility of all the business operations of the company prior to its acquisition by Becton, Dickinson and Company in December last year.
According to the Chairman and CEO of Celgene Corporation, Mark Alles, John is an accomplished leader in the healthcare industry with significant expertise and experience across therapeutic areas and geographies. He said that the leadership and insight of Mr. Weiland will help to inform and direct the long-term growth strategy of Celgene.